Back to Search
ROBERT MULLIN, DO
DO
Pediatrics Physician
NPI: 1356978183IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
OS023514C(PA)
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
02008753A(IN)OS023514C(PA)
Education
OTHER
Class of 2020
Research & Publications (15)
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
PMID 19028424·Bioorg Med Chem Lett·2009
7-preclinical
6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases.
PMID 18287036·Proc Natl Acad Sci U S A·2008
4-observational
Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia.
PMID 18425366·Oncol Rep·2008
7-preclinical
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
PMID 19047120·Clin Cancer Res·2008
3-trial
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
PMID 17635524·Cell Prolif·2007
8-other
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
PMID 17620431·Mol Cancer Ther·2007
7-preclinical
Effects of syringe material, sample storage time, and temperature on blood gases and oxygen saturation in arterialized human blood samples.
PMID 16800906·Respir Care·2006
2-rct
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
PMID 16452222·Cancer Res·2006
7-preclinical
Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.
PMID 15328520·Br J Cancer·2004
7-preclinical
Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
PMID 12639547·Bioorg Med Chem Lett·2003
7-preclinical
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
PMID 12214266·Oncogene·2002
8-other
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
PMID 12467226·Mol Cancer Ther·2001
4-observational
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
PMID 11585755·Cancer Res·2001
7-preclinical
Development of the ICD-10 procedure coding system (ICD-10-PCS).
PMID 11234732·Top Health Inf Manage·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 4 locations total
- Address
- 800 PENNSYLVANIA AVE
CHARLESTON, WV 25302 - Phone
- (304) 388-5432
Quick Facts
- NPI
- 1356978183
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 4
- Years in Practice
- 6
- Publications
- 15
Are you this provider?
Claim Your Profile